Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. (25th September 2021)

• Record Type: Journal Article
• Authors: Gay, Cynthia L; James, Katherine S; Tuyishime, Marina; Falcinelli, Shane D; Joseph, Sarah B; Moeser, Matthew J; Allard, Brigitte; Kirchherr, Jennifer L; Clohosey, Matthew; Raines, Samuel L M; Montefiori, David C; Shen, Xiaoying; Gorelick, Robert J; Gama, Lucio; McDermott, Adrian B; Koup, Richard A; Mascola, John R; Floris-Moore, Michelle; Kuruc, JoAnn D; Ferrari, Guido; Eron, Joseph J; Archin, Nancie M; Margolis, David M
• Is Part Of: Journal of infectious diseases. Volume 225:Number 5(2022)
• Page Start: 856
• Page End: 861
• Publication Date: 2021-09-25
• Subjects: HIV latency -- broadly neutralizing antibody -- latency reversal; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab487
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell–associated HIV RNA (rca-RNA) was measured, and intact proviral DNA assay (IPDA) and quantitative viral outgrowth assay (QVOA) were performed at baseline and posttreatment. In 3 participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natural decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. Clinical Trials Registration . NCT03803605.